• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Calistoga Pharmaceuticals

edit

Calistoga Pharmaceuticals is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. Calistoga Pharmaceuticals has a portfolio of proprietary compounds selectively targeting the isoforms of the PI3 kinase pathway.

Milestones

edit

• 
  Calistoga Pharmaceuticals added Andrew Guggenhime as CFO. (9/29/10)
  Posted 9/29/10 at 5:32pm
• 
  Calistoga Pharmaceuticals received $40M in Series C funding. (6/30/10)
  Posted 6/30/10 at 5:59pm via calistogapharma.com
• 
  Calistoga Pharmaceuticals received $21M in Series A funding. (3/5/07)
  Posted 3/11/10 at 11:39pm via calistogapharma.com
• 
  Calistoga Pharmaceuticals received $30M in Series B funding. (5/5/09)
  Posted 7/7/09 at 12:25pm
• 
  Calistoga Pharmaceuticals was acquired by Gilead Sciences for $375M. (2/22/11)
  Posted 2/22/11 at 9:50pm via gilead.com

Videos

Screenshots

edit

Above: Calistoga Pharmaceuticals
Uploaded: 10/30/09

Sources

1. Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million (investors.gilead.com) [edit]
2. Calistoga Pharmaceuticals, a newly formed drug development company, announces its formation and completion of a $21 million Series A financing (calistogapharma.com) [edit]
3. Capital Report Index [edit]
4. Calistoga Pharmaceuticals Raises $40 Million in Series C Financing (calistogapharma.com) [edit]